STAAR Surgical Company (STAA) Insider Trading Activity

NASDAQ$20.06-0.91 (-4.34%)
Market Cap
$1.04B
Sector
Healthcare
Industry
Medical—Instruments & Supplies
Rank in Sector
4 of 893
Rank in Industry
1 of 49

STAA Insider Trading Activity

STAA Median Price and Trade Amounts History Chart

Statistics of Insider Transactions

Amount of Insider Buys and Sells

Buys
$94,113,089
30
100
Sells
$0
0
0

Related Transactions

BROADWOOD PARTNERS, L.P.10 percent owner
30
$94.11M
0
$0
$94.11M

About STAAR Surgical Company

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides Visian implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia; and Hyperopic ICL, which treats far-sightedness. It also offers preloaded silicone cataract intraocular lenses and injector systems for use in cataract surgery. In addition, the company sells injector parts, and other related instruments and devices. It markets its products to health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors, as well as products are primarily used by ophthalmologists. The company sells its products directly through its sales representatives in the United States, Japan, Germany, Spain, Canada, the United Kingdom, and Singapore, as well as through own representatives and independent distributors in China, Korea, India, France, Benelux, Italy, and internationally. STAAR Surgical Company was incorporated in 1982 and is headquartered in Lake Forest, California.

Insider Activity of STAAR Surgical Company

Over the last 12 months, insiders at STAAR Surgical Company have bought $94.11M and sold $0 worth of STAAR Surgical Company stock.

On average, over the past 5 years, insiders at STAAR Surgical Company have bought $41.52M and sold $98.96M worth of stock each year.

Highest buying activity among insiders over the last 12 months: BROADWOOD PARTNERS, L.P. (10 percent owner) — $94.11M.

The last purchase of 27,485 shares for transaction amount of $606,138 was made by BROADWOOD PARTNERS, L.P. (10 percent owner) on 2026‑01‑09.

List of Insider Buy and Sell Transactions, STAAR Surgical Company

2026-01-09PurchaseBROADWOOD PARTNERS, L.P.10 percent owner
27,485
0.0554%
$22.05
$606,138
-4.87%
2026-01-08PurchaseBROADWOOD PARTNERS, L.P.10 percent owner
3,240
0.0064%
$21.94
$71,082
-5.17%
2026-01-07PurchaseBROADWOOD PARTNERS, L.P.10 percent owner
66,467
0.1333%
$22.00
$1.46M
-1.66%
2026-01-06PurchaseBROADWOOD PARTNERS, L.P.10 percent owner
336,946
0.6154%
$21.62
$7.28M
+2.77%
2025-11-21PurchaseBROADWOOD PARTNERS, L.P.10 percent owner
797,486
1.605%
$27.86
$22.22M
-14.95%
2025-11-20PurchaseBROADWOOD PARTNERS, L.P.10 percent owner
393,382
0.7895%
$27.14
$10.68M
-12.61%
2025-11-19PurchaseBROADWOOD PARTNERS, L.P.10 percent owner
309,132
0.6245%
$26.42
$8.17M
-9.47%
2025-04-10PurchaseBROADWOOD PARTNERS, L.P.10 percent owner
900
0.0017%
$15.18
$13,658
+52.94%
2025-04-09PurchaseBROADWOOD PARTNERS, L.P.10 percent owner
8,200
0.0155%
$15.08
$123,676
+49.50%
2025-04-08PurchaseBROADWOOD PARTNERS, L.P.10 percent owner
178,127
0.3428%
$15.32
$2.73M
+56.98%
2025-04-07PurchaseBROADWOOD PARTNERS, L.P.10 percent owner
138,054
0.2707%
$15.61
$2.16M
+46.53%
2025-04-04PurchaseBROADWOOD PARTNERS, L.P.10 percent owner
497,631
1.0082%
$15.91
$7.92M
+48.18%
2025-04-03PurchaseBROADWOOD PARTNERS, L.P.10 percent owner
209,535
0.4142%
$16.97
$3.56M
+35.23%
2025-04-02PurchaseBROADWOOD PARTNERS, L.P.10 percent owner
31,780
0.0638%
$17.43
$553,925
+33.69%
2025-03-31PurchaseBROADWOOD PARTNERS, L.P.10 percent owner
22,189
0.0445%
$17.46
$387,360
+33.30%
2025-03-28PurchaseBROADWOOD PARTNERS, L.P.10 percent owner
8,131
0.0162%
$17.47
$142,014
+31.96%
2025-03-27PurchaseBROADWOOD PARTNERS, L.P.10 percent owner
3,620
0.0073%
$17.48
$63,294
+33.41%
2025-03-26PurchaseBROADWOOD PARTNERS, L.P.10 percent owner
101,633
0.2052%
$17.50
$1.78M
+33.21%
2025-03-25PurchaseBROADWOOD PARTNERS, L.P.10 percent owner
34,296
0.0695%
$17.44
$598,177
+33.89%
2025-03-21PurchaseBROADWOOD PARTNERS, L.P.10 percent owner
102,400
0.2078%
$17.74
$1.82M
+31.37%
Total: 388
*Gray background shows transactions not older than one year

Insider Historical Profitability

8.78%
BROADWOOD PARTNERS, L.P.10 percent owner
15453629
31.257%
$324.06M16828
+8.7%
BAILEY DAVIDPresident, Int'l Operations
1127800
2.2811%
$23.65M018
Caldwell Barry GPresident and CEO
251839
0.5094%
$5.28M41
+5.27%
BAILEY DON Mdirector
145139
0.2936%
$3.04M30
+7%
CURTIS NICHOLAS TSr. VP Sales
112990
0.2285%
$2.37M12
<0.0001%
Mason Caren LPresident & CEO
83645
0.1692%
$1.75M110
+1.38%
Blickensdoerfer Hans-MartinSr. VP, Comm. Ops, China
77200
0.1561%
$1.62M012
DUFFY DONALDdirector
54000
0.1092%
$1.13M22
+3.35%
MORRISON DAVID Rdirector
40000
0.0809%
$838,800.0004
Francese James ESr. VP, Comm. Ops., NA, APAC
34908
0.0706%
$732,020.76013
Kaufman Charles SV.P. , General Counsel
33500
0.0678%
$702,495.0012
<0.0001%
ANDREWS DEBORAH JChief Financial Officer
31267
0.0632%
$655,668.99020
Holliday KeithChief Technology Officer
27633
0.0559%
$579,464.01016
Gesten Samuel JChief Legal Officer
27583
0.0558%
$578,415.51010
Williams Patrick F.Chief Financial Officer
25619
0.0518%
$537,230.4302
Kamijo IsamuPresident, STAAR Japan Inc.
23334
0.0472%
$489,313.9801
Moore John Cdirector
21387
0.0433%
$448,485.3942
+39.87%
LOGAN MARK Bdirector
19600
0.0396%
$411,012.0040
+21.63%
Hughes RobinVice President, R&D
19575
0.0396%
$410,487.75210
<0.0001%
MEIER RICHARD Adirector
18300
0.037%
$383,751.0032
+42.69%
Wall William Pdirector
16235
0.0328%
$340,447.9501
GOODMEN WILLIAM WALTERGlobal VP, Human Resources
15000
0.0303%
$314,550.0006
Barnes Scott DChief Medical Officer
11032
0.0223%
$231,341.0401
WEISNER AIMEE Sdirector
10864
0.022%
$227,818.0820
<0.0001%
SCHLOTTERBECK DAVID Ldirector
10000
0.0202%
$209,700.0010
+47.13%
FAGEN DONALD LV.P. Sales for N. America
9300
0.0188%
$195,021.0002
Hansen Graydon C.Sr. VP, Global Operations
8847
0.0179%
$185,521.5906
Felberg CraigVP, R&D and Clinical Affairs
8700
0.0176%
$182,439.0003
Hayashida Jon K.VP, Global Clinical, Medical
8342
0.0169%
$174,931.7408
Todd Donald JPresident, Asia/Pacific
7500
0.0152%
$157,275.0003
Butcher Arthur Cdirector
4208
0.0085%
$88,241.7610
<0.0001%
SILVERMAN LOUdirector
2924
0.0059%
$61,316.2812
<0.0001%
Lin Elizabeth Yeudirector
2855
0.0058%
$59,869.3510
<0.0001%
Zhou Lilian Yanshengdirector
2327
0.0047%
$48,797.1910
+11.37%
ROUSH JACK STEVENdirector
1000
0.002%
$20,970.0010
<0.0001%
*Gray background shows insiders who have made transactions during last year

STAA Institutional Investors: Active Positions

Increased Positions109+46.98%12M+22.96%
Decreased Positions105-45.26%15M-27.55%
New Positions64New10MNew
Sold Out Positions40Sold Out8MSold Out
Total Postitions236+1.72%51M-4.59%

STAA Ownership Change vs Market

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
Broadwood Capital Inc$319,060.0027.04%13.52M00%2025-09-30
Blackrock, Inc.$171,311.0014.52%7.26M-112,193-1.52%2025-09-30
Vanguard Group Inc$100,751.008.54%4.27M-121,644-2.77%2025-09-30
Yunqi Capital Ltd$59,001.005%2.5M+88,773+3.68%2025-09-30
State Street Corp$45,098.003.82%1.91M-91,941-4.59%2025-09-30
Balyasny Asset Management L.P.$42,799.003.63%1.81M+2MNew2025-09-30
Magnetar Financial Llc$28,423.002.41%1.2M+1MNew2025-09-30
Geode Capital Management, Llc$27,702.002.35%1.17M-18,998-1.59%2025-09-30
Goldman Sachs Group Inc$23,040.001.95%976,259+794,020+435.7%2025-09-30
Alpine Associates Management Inc.$21,549.001.83%913,087+913,087New2025-09-30

Financial Ratios

Summary
Comparison with Competitors

Price to Earnings

Price/Earnings to Growth

Price to Sales

Price to Book

Price/Free Cash Flow

Analyst Recommendations

Analyst Price Targets

Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.